The ESMO Immuno-Oncology Congress 2018 programme is now online!
The ESMO Immuno-Oncology Congress is an annual event devoted entirely to the development and use of the immunotherapies against cancer.
Delegates will learn how to apply the latest standards of care in the immunotherapy of cancer and the world's leading specialists will discuss a full range of topics including:
- Cancer neoantigens
- Personalised vaccines
- Intratumoural immunotherapy
- Predictive biomarkers
- Imaging and nuclear medicine
- Management of side effects
- Innovative technological developments
- What’s new in specific cancer types
- Adoptive T cell therapy
CME: The ESMO Immuno-Oncology Congress 2018 programme has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 21 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit he/she actually spent in the educational activity.
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found online here.
ESMO-MORA: The ESMO Immuno-Oncology Congress 2018 programme has been accredited with 25 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. See here for further details.
The Congress webcasts will include all the sessions of the official programme, where Speaker permission is granted, and will be available on this website and OncologyPRO for ESMO members.